Arcadia End Period Cash Flow vs Cash Conversion Cycle Analysis
| RKDA Stock | USD 2.74 0.15 5.79% |
Arcadia Biosciences financial indicator trend analysis is way more than just evaluating Arcadia Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Arcadia Biosciences is a good investment. Please check the relationship between Arcadia Biosciences End Period Cash Flow and its Cash Conversion Cycle accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcadia Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.
End Period Cash Flow vs Cash Conversion Cycle
End Period Cash Flow vs Cash Conversion Cycle Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Arcadia Biosciences End Period Cash Flow account and Cash Conversion Cycle. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Arcadia Biosciences' End Period Cash Flow and Cash Conversion Cycle is -0.25. Overlapping area represents the amount of variation of End Period Cash Flow that can explain the historical movement of Cash Conversion Cycle in the same time period over historical financial statements of Arcadia Biosciences, assuming nothing else is changed. The correlation between historical values of Arcadia Biosciences' End Period Cash Flow and Cash Conversion Cycle is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which End Period Cash Flow of Arcadia Biosciences are associated (or correlated) with its Cash Conversion Cycle. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash Conversion Cycle has no effect on the direction of End Period Cash Flow i.e., Arcadia Biosciences' End Period Cash Flow and Cash Conversion Cycle go up and down completely randomly.
Correlation Coefficient | -0.25 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
End Period Cash Flow
Cash Conversion Cycle
Most indicators from Arcadia Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Arcadia Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcadia Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.At present, Arcadia Biosciences' Tax Provision is projected to decrease significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 11.4 M, whereas Selling General Administrative is forecasted to decline to about 14.7 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 26.8M | 19.6M | 16.0M | 21.7M | Cost Of Revenue | 8.7M | 9.8M | 3.3M | 3.1M |
Arcadia Biosciences fundamental ratios Correlations
Click cells to compare fundamentals
Arcadia Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Arcadia Biosciences fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 32.6M | 47.3M | 43.9M | 28.9M | 19.7M | 35.9M | |
| Other Current Liab | 4.5M | 3.0M | 1.5M | 1.3M | 1.1M | 1.8M | |
| Total Current Liabilities | 5.7M | 6.3M | 5.0M | 4.2M | 3.6M | 4.1M | |
| Total Stockholder Equity | 7.7M | 27.7M | 31.1M | 21.0M | 12.8M | 14.6M | |
| Property Plant And Equipment Net | 3.8M | 9.4M | 5.4M | 2.6M | 1.2M | 1.1M | |
| Current Deferred Revenue | 42K | 8K | 64K | (572K) | (514.8K) | (489.1K) | |
| Net Debt | (6.2M) | (4.7M) | (25.4M) | (18.6M) | (5.5M) | (5.8M) | |
| Retained Earnings | (207.2M) | (211.8M) | (226.5M) | (257.9M) | (271.8M) | (285.4M) | |
| Accounts Payable | 492K | 726K | 1.4M | 905K | 801K | 970.9K | |
| Cash | 8.4M | 14.0M | 28.7M | 20.6M | 6.5M | 6.2M | |
| Non Current Assets Total | 4.1M | 15.7M | 8.5M | 3.5M | 4.7M | 5.5M | |
| Non Currrent Assets Other | 372K | 5.5M | 2.7M | 932K | 3.5M | 2.5M | |
| Cash And Short Term Investments | 25.3M | 25.7M | 28.7M | 20.6M | 11.6M | 11.1M | |
| Net Receivables | 602K | 1.4M | 1.4M | 1.2M | 514K | 767.9K | |
| Common Stock Shares Outstanding | 159.1K | 249.0K | 532.0K | 599.4K | 1.2M | 1.3M | |
| Liabilities And Stockholders Equity | 32.6M | 47.3M | 43.9M | 28.9M | 19.7M | 35.9M | |
| Non Current Liabilities Total | 18.5M | 12.5M | 7.7M | 3.8M | 3.4M | 3.2M | |
| Inventory | 1.8M | 3.8M | 4.4M | 2.6M | 2.0M | 1.6M | |
| Other Current Assets | 712K | 1.6M | 1.8M | 1.2M | 858K | 914.0K | |
| Other Stockholder Equity | 214.8M | 239.5M | 257.5M | 278.8M | 284.5M | 207.1M | |
| Total Liab | 24.2M | 18.8M | 12.7M | 8.0M | 7.0M | 6.7M | |
| Property Plant And Equipment Gross | 3.8M | 9.4M | 5.4M | 2.6M | 3.7M | 2.7M | |
| Total Current Assets | 28.4M | 31.7M | 35.4M | 25.4M | 15.0M | 28.3M | |
| Accumulated Other Comprehensive Income | (4.8M) | 1K | 0.0 | 101K | 116.2K | 122.0K | |
| Other Liab | 8.2M | 16.9M | 5.0M | 5.5M | 6.3M | 8.1M | |
| Other Assets | 372K | 5.5M | 2.7M | 1.0 | 0.9 | 0.86 | |
| Short Term Debt | 635K | 2.6M | 2.1M | 2.0M | 1.7M | 1.6M | |
| Property Plant Equipment | 1.1M | 2.2M | 9.4M | 5.4M | 6.2M | 3.1M | |
| Net Tangible Assets | 12.8M | 7.7M | 26.9M | 30.6M | 35.2M | 37.0M | |
| Common Stock Total Equity | 42K | 45K | 49K | 54K | 62.1K | 51.0K | |
| Retained Earnings Total Equity | (167.3M) | (178.4M) | (207.2M) | (211.8M) | (190.6M) | (200.2M) | |
| Short Term Investments | 9.8M | 16.9M | 11.6M | 0.0 | 5.1M | 4.9M | |
| Capital Surpluse | 175.2M | 191.1M | 214.8M | 239.5M | 275.4M | 213.9M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Arcadia Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Arcadia Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Arcadia Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Arcadia Biosciences Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcadia Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Agricultural Products & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcadia Biosciences. If investors know Arcadia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcadia Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.285 | Earnings Share (6.77) | Revenue Per Share 3.802 | Quarterly Revenue Growth (0.04) | Return On Assets (0.39) |
The market value of Arcadia Biosciences is measured differently than its book value, which is the value of Arcadia that is recorded on the company's balance sheet. Investors also form their own opinion of Arcadia Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Arcadia Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcadia Biosciences' market value can be influenced by many factors that don't directly affect Arcadia Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcadia Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcadia Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcadia Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.